Chapter 24

CNS Depressants for Psychosis & Anxiety — Study Guide Fast Notes

1) Big Picture

  • CNS Depressants used for psychosis and anxiety:

    • Antipsychotics

    • Also known as NEUROLEPTICS. Preferred terms: antipsychotics or neuroleptics.

    • Anxiolytics

    • Also known as ANTIANXIETY medications; many are sedative-hypnotics.

  • Overlap of Uses: Some anxiolytics also treat:

    • Insomnia

    • Seizures

    • Alcohol withdrawal

    • Procedural sedation

  • Key Risks:

    • Antipsychotics:

    • ↓ dopamine

    • Risk of Extrapyramidal Symptoms (EPS) and Neuroleptic Malignant Syndrome (NMS)

    • Benzodiazepines:

    • Risk of sedation, tolerance/dependence, and withdrawal

2) Psychopathology & Neurochemistry

  • Synaptic Basics:

    • Presynaptic vesicles release neurotransmitters (NT) into the synaptic cleft → bind to postsynaptic receptors → signal → removal by enzymes, diffusion, or reuptake.

  • Neurotransmitters Linked to Disorders:

    • GABA (Gamma-Aminobutyric Acid):

    • ↓ GABA levels lead to ↑ anxiety.

    • Benzodiazepines bind to GABA_A receptor sites, increasing the effect of GABA.

    • Dopamine (DA):

    • Modulates cognition, emotion, and motivation.

    • Dysregulation is associated with disorders like schizophrenia/psychosis and depression.

    • Other relevant neurotransmitters:

    • Serotonin

    • Norepinephrine

    • Acetylcholine

3) Psychosis & Schizophrenia Symptoms

  • Psychosis:

    • Characterized by a loss of reality, leading to disorganized thought, impaired processing, delusions, hallucinations, catatonia, and aggression.

  • Schizophrenia Symptom Clusters:

    • Cognitive Symptoms:

    • Disorganized thinking, memory deficits, focus deficits.

    • Positive Symptoms:

    • Agitation, hallucinations, delusions, paranoia, and incoherence.

    • Negative Symptoms:

    • Avolition (lack of motivation), alogia (lack of speech), blunted affect, poor self-care, social withdrawal (more chronic).

4) Antipsychotics Overview

  • Mechanism of Action:

    • All antipsychotics block dopamine receptors.

    • Specifically, D₂ blockade drives the antipsychotic effect and causes EPS.

    • Atypicals (2nd-generation antipsychotics):

    • Weaker D₂ blockage, but stronger D₄ and serotonin (5-HT) blockade, effective for treating positive and negative symptoms with fewer EPS.

  • Other Effects:

    • Many antipsychotics block the Chemoreceptor Trigger Zone (CTZ)/vomiting center, serving as antiemetics.

  • Categories & Exemplars:

    • Typical (1st-generation):

    • Phenothiazines:

      • Subgroups:

      • Aliphatic (Chlorpromazine; effects: sedation, hypotension),

      • Piperazine (Fluphenazine, Perphenazine; ↑ EPS),

      • Piperidine (Thioridazine; strong sedation with fewer EPS).

    • Nonphenothiazines:

      • Haloperidol (potent with ↑ EPS), Loxapine, Molindone, Thiothixene.

    • Atypical (2nd-generation):

    • Examples include Clozapine, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone, Iloperidone, Cariprazine, Brexpiprazole, Lumateperone.

    • Treat both positive and negative symptoms, with decreased overall EPS.

  • Dosing & Kinetics Pearls:

    • Oral liquid formulations absorb faster; ensure checks for cheeking.

    • Highly protein-bound; slow excretion; urine may turn pink to red-brown with phenothiazines (benign).

    • Clinical response onset: some benefit in 7–10 days; full effect in 3–6 weeks.

    • Long-acting depot forms: Fluphenazine decanoate, Haloperidol decanoate (administered every 2–4 weeks; Z-track method; rotate injection sites; do not massage injection site; do not leave in plastic syringe for >15 min).

5) Adverse Effects & Emergencies

  • Extrapyramidal Symptoms (EPS):

    • Pseudoparkinsonism:

    • Timing: Days to weeks

    • Features: Tremor, rigidity, bradykinesia, masklike facies, shuffling gait

    • Management: ↓ dose; administer anticholinergics (e.g., Benztropine).

    • Acute Dystonia:

    • Timing: Hours to days (~5%)

    • Features: Painful spasms in face/tongue/neck/back; oculogyric crisis; laryngeal spasm.

    • Management: IM/IV Benztropine; Lorazepam as adjunct treatment.

    • Akathisia:

    • Timing: Days to weeks (~20%)

    • Features: Motor restlessness, pacing, rocking movements.

    • Management: Beta-blocker (Propranolol) or benzodiazepine (Lorazepam).

    • Tardive Dyskinesia:

    • Timing: Months to years (20–30% with long-term use)

    • Features: Tongue protrusion/rolling, lip smacking, choreoathetoid movements.

    • Management: Stop offending agent, consider switching to Clozapine; VMAT2 inhibitors like Tetrabenazine; Vit E or Amantadine may be used.

    • Neuroleptic Malignant Syndrome (NMS):

    • Rare but life-threatening.

    • Symptoms: Severe muscle rigidity, hyperthermia, altered mental status (AMS), diaphoresis, blood pressure fluctuation, tachycardia, dysrhythmias, ↑ creatine kinase (CK), rhabdomyolysis, renal failure, seizures.

    • Treatment: Discontinue antipsychotic immediately, administer aggressive IV hydration, cooling methods, benzodiazepines, dantrolene; ICU care may be necessary.

  • Other Common Effects:

    • Anticholinergic Symptoms:

    • Dry mouth, constipation, urinary retention, tachycardia.

    • Orthostatic Hypotension: Risk for falls, especially in elderly patients.

    • Photosensitivity: Patients should be advised on sun protection.

    • Blood Dyscrasias:

    • Risk of agranulocytosis (especially with Clozapine); WBC/ANC monitoring is essential.

    • Metabolic Effects:

    • Weight gain, hyperglycemia, and dyslipidemia (notably with Olanzapine, Quetiapine, Risperidone).

    • Cardiac Effects:

    • Ziprasidone risk of QT prolongation; avoid use in patients with prolonged QT and regular ECG monitoring is advised.

  • Herb Interactions (selected):

    • Kava Kava: Increases risk of dystonia when used with phenothiazines/Fluphenazine.

    • Ginkgo: May potentiate effects of Haloperidol/Olanzapine/Clozapine.

    • St. John's Wort: Decreases Clozapine levels.

6) Phenothiazines at a Glance

  • Group Characteristics:

  • Aliphatic:

    • Sedation: +++

    • Hypotension: +++

    • EPS: ++

    • Antiemetic: ++/+++

    • Chlorpromazine: Marked orthostasis noted.

  • Piperazine:

    • Sedation: ++

    • Hypotension: +

    • EPS: +++

    • Antiemetic: +++

    • Fluphenazine/Perphenazine: Noted for ↑ EPS.

  • Piperidine:

    • Sedation: +++

    • Hypotension: +++

    • EPS: +

    • Antiemetic: –

    • Thioridazine: Strong sedation observed with fewer EPS.

7) Nonphenothiazines (1st-generation)

  • Haloperidol:

    • Mechanism: Potent D₂ blockade causing ↑ EPS.

    • Administration caution: Use lower doses in older adults; photosensitivity precautions necessary.

  • Loxapine, Molindone, Thiothixene:

    • Potency: Moderate to high; ↑ EPS noted and variable sedation/orthostasis.

8) Atypical Antipsychotics (2nd-generation) — Pros & Cons

  • Pros:

    • Effective in treating both positive & negative symptoms with fewer EPS/Tardive Dyskinesia (TD) compared to older agents.

  • Cons:

    • Metabolic syndrome risk (increased weight, glucose, lipids); some have sedation and orthostatic effects.

  • Drug Pearls:

    • Clozapine: Effective for treatment-resistant cases but has significant agranulocytosis risk. Discontinue if WBC < 3000/mm³.

    • Risperidone: Generally low EPS risk at moderate doses but may cause weight gain, akathisia, sedation, and increased appetite.

    • Ziprasidone: Risk of QT prolongation; ECG telemetry is warranted; contraindicated in patients with prolonged QT.

    • Aripiprazole: Functions as partial D₂ agonist; may lead to impulse-control issues.

9) Special Populations & Safety

  • Older Adults:

    • Utilize 25–50% of the adult dose; black-box warning for increased mortality in dementia-related psychosis.

  • Pregnancy/Lactation:

    • Potential teratogenic effects or infant effects; use with caution and balance risks versus benefits; many medications can pass into breast milk.

  • Smoking: Increases metabolism for some antipsychotics, resulting in lower drug levels.

  • Caution: Do not administer multiple antipsychotics routinely; consider switching rather than layering medications.

10) Drug Interactions (High-Yield)

  • Additive CNS Depression: Caution with alcohol, opioids, sedatives, and benzodiazepines.

  • Additive Hypotension: Interaction with antihypertensives can lead to significant blood pressure drops.

  • Lowered Seizure Threshold: Phenothiazines may require higher doses of anticonvulsants.

  • Antacids: Inhibit phenothiazine absorption; should be administered 1 hour before or 2 hours after.

11) Anxiolytics: Benzodiazepines (Major Class)

  • Mechanism of Action:

    • Potentiate GABA → Increase frequency of chloride channel opening at GABA_A receptor → Resulting in CNS inhibition.

  • Uses:

    • Anxiety (short-term), insomnia (some efficacy), status epilepticus, muscle spasms, preoperative sedation, alcohol withdrawal.

  • Common Agents:

    • Lorazepam (prototype), Alprazolam, Diazepam, Clonazepam, Chlordiazepoxide, Oxazepam, Clorazepate, Midazolam.

  • Adverse Effects:

    • Commonly experience sedation, dizziness, ataxia, dry mouth, blurred vision, constipation; risks of tolerance, dependence, and withdrawal symptoms.

  • Overdose Management:

    • Assess airway and administer oxygen; gastric decontamination may be utilized; IV fluids may be required; Flumazenil (caution with seizure risk).

  • Withdrawal: Abrupt discontinuation should be avoided; tapering is necessary, especially for short-acting agents, which may lead to withdrawal symptoms sooner.

  • Avoid With:

    • Alcohol or other CNS depressants; Kava Kava can increase sedation; smoking and caffeine can decrease the effect of benzodiazepines.

12) Buspirone (Azapirone)

  • Mechanism of Action:

    • Acts on serotonin (5-HT) and dopamine (DA) receptors (not a benzodiazepine).

  • Onset: 1-2 weeks continuous use is required for effects.

  • Pros:

    • Minimally sedating with a low risk of dependence.

  • Caution:

    • Grapefruit juice increases levels, so consumption should be limited to ≤ 8 ounces/day or one-half grapefruit.

13) Nursing Process — Quick Checklist

  • Assessment:

    • Evaluate baseline vital signs, mental status, and comorbid conditions like cardiac, ocular, or respiratory diseases.

    • Assess current medications including anticonvulsants, antihypertensives, CNS depressants, and herbal supplements.

    • For benzodiazepines: Assess suicide risk and support system availability.

  • Planning/Goals:

    • Aiming for a calmer emotional state, improved communication, maintenance of activities of daily living (ADLs), organized thought processes, improved reality testing, improved sleep patterns (especially for anxiety).

  • Interventions:

    • Administer medication with food or milk to decrease gastrointestinal upset (common with many typical antipsychotics).

    • Liquid formulations (specifically phenothiazines): dilute in fruit juice, water, or milk while avoiding apple juice/caffeine for Fluphenazine; protect from light, and avoid skin contact.

    • Remain with the patient until the medication is swallowed to prevent cheeking.

    • When administering IM depot injections: use deep Z-track technique; rotate injection sites; avoid massaging the site.

    • Monitor parameters including orthostatic blood pressure (30 minutes post-injection), occurrence of EPS, NMS, glucose levels, and WBC/ANC counts (especially with Clozapine); monitor urine output for retention.

    • Engage with the patient in therapeutic interactions and support groups.

14) Patient Teaching

  • Adherence:

    • Emphasize that antipsychotics are not curative and simply help control symptoms; advise against abrupt discontinuation.

  • Onset:

    • Educate that full benefits may take weeks to manifest.

  • Precautions:

    • Advise patients to avoid alcohol and other CNS depressants, and refrain from driving until the medication’s effects are stabilized.

    • Emphasize sun protection measures; recommend rising slowly to prevent orthostasis.

    • Stress proper oral hygiene; inform that a benign red-brown urine effect may occur with phenothiazines.

    • Report any signs of infection (e.g., sore throat, fever), EPS symptoms, or severe dizziness/syncope, and symptoms indicative of NMS.

    • Provide counseling on the need for smoking cessation and contraception; consider recommending an identification bracelet for patients taking high-risk medications.

15) Rapid Drug Cards (High-Yield)

  • Fluphenazine (Piperazine Phenothiazine):

    • Uses: Schizophrenia/Psychosis, available in PO/IM routes and as depot formulations.

    • Mechanism: D₂ blockade.

    • Notables: ↑ EPS, orthostatic effects, photosensitivity; strong protein binding (~99%); long half-life (depot lasts weeks).

    • Serious Risks: Dysrhythmias, blood dyscrasia, NMS.

    • Overdose management includes airway management, gastric lavage/charcoal, hydration, and administration of anticholinergics, and norepinephrine if needed.

  • Haloperidol / Haloperidol Decanoate:

    • Uses: Acute psychosis, schizophrenia, administered PO/IM; depot IM once monthly.

    • Mechanism: D₂ blockade; potent, ↑ EPS.

    • Notables: QT concerns are observed, though less compared to Ziprasidone; necessitates monitoring and dose reduction in older patients.

  • Aripiprazole (Atypical):

    • Uses: Schizophrenia, bipolar disorder, MDD adjunct, autism, Tourette’s; administered PO and via Long-Acting Injection (LAI).

    • Mechanism: Modulates both DA and serotonin (5-HT).

    • Risks: Potential metabolic changes, EPS possible, impulse-control issues, NMS; grapefruit can increase levels, and SSRIs raise the risk of serotonin syndrome.

  • Lorazepam (Benzodiazepine):

    • Uses: Anxiety, status epilepticus, sedation, insomnia.

    • Mechanism: Potentiates GABA.

    • Risks: Sedation, potential for dependence; may raise levels when used with Cimetidine; interactions with alcohol and CNS depressants increase respiratory depression risk.

  • Buspirone:

    • Uses: Generalized Anxiety Disorder (GAD), scheduled administration.

    • Onset: Takes 1-2 weeks, offering no PRN relief.

    • Avoid excessive grapefruit consumption due to increased levels.

16) Practice Q&A (from study set)

  1. Acute dystonia → b.

  2. Blocks dopamine → a.

  3. EPS with fluphenazine → d.

  4. Atypicals → a. Clozapine, d. Olanzapine, e. Aripiprazole.

  5. Lorazepam truths → a.

  6. Aripiprazole nursing care → b, c, d, e.

  7. Phenothiazine overdose care → a, b, c, f. (Rationales match the explanations in your text.)

17) Mnemonics & Exam Tips

  • EPS Timeline: “Park* (days) → Akathisia (days–weeks) → Dystonia (hours–days) → Tardive (months–years)”* (Remember that dystonia can be the earliest symptom; know treatments).

  • NMS Red Flags: Lead-pipe rigidity + Hyperthermia + AMS + Autonomic instability → “LaHAA” → Action: Stop drug + Administer Dantrolene.

  • Clozapine Labs: “CLOZed club needs a Bouncer (ANC/WBC)”.

  • Benzodiazepine Safety: “Don’t mix BENZO with BOoze” (CNS depression risk).

  • Ziprasidone: “Zip the QT” → Check ECG regularly.